Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial

被引：8
作者：
Khoo, Chee W. [1 ]
Lip, Gregory Y. H. [1 ]
机构：
[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 04期
关键词：
atrial fibrillation; dabigatran; direct thrombin inhibitor; stroke; DESIGN;
D O I：
10.1517/14656560903530691
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Oral anticoagulants such as warfarin have been used widely for the treatment of venous thromboembolism and stroke prevention in atrial fibrillation (AF) patients. Warfarin has significant limitations and also requires frequent monitoring. Thus, there is an unmet need, with the quest for alternative oral anticoagulants with stable pharmacokinetics and pharmacodynamics that do not need monitoring. The paper under evaluation provides us with up-to-date information on the safety and efficacy of a new oral anticoagulant, dabigatran, compared with warfarin for stroke prevention in AF patients.</.
引用
收藏
页码：685 / 687
页数：3
相关论文
共 7 条
  • [1] The pharmacology and management of the vitamin K antagonists
    Ansell, J
    Hirsh, J
    Poller, L
    Bussey, H
    Jacobson, A
    Hylek, E
    [J]. CHEST, 2004, 126 (03) : 204S - 233S
  • [2] Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Yusuf, Salim
    Eikelboom, John
    Oldgren, Jonas
    Parekh, Amit
    Pogue, Janice
    Reilly, Paul A.
    Themeles, Ellison
    Varrone, Jeanne
    Wang, Susan
    Alings, Marco
    Xavier, Denis
    Zhu, Jun
    Diaz, Rafael
    Lewis, Basil S.
    Darius, Harald
    Diener, Hans-Christoph
    Joyner, Campbell D.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) : 1139 - 1151
  • [3] Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
    Ezekowitz, Michael D.
    Connolly, Stuart
    Parekh, Amit
    Reilly, Paul A.
    Varrone, Jeanne
    Wang, Susan
    Oldgren, Jonas
    Themeles, Ellison
    Wallentin, Lars
    Yusuf, Salim
    [J]. AMERICAN HEART JOURNAL, 2009, 157 (05) : 805 - 810
  • [4] Clinical trial design issues: At least 10 things you should look for in clinical trials
    Glasser, Stephen P.
    Howard, George
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (10) : 1106 - 1115
  • [5] Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism
    Haas, S
    [J]. DRUGS, 2004, 64 (Suppl 1) : 7 - 16
  • [6] Antithrombotic treatment in real-life atrial fibrillation patients:: a report from the Euro Heart Survey on Atrial Fibrillation
    Nieuwlaat, Robby
    Capucci, Alessandro
    Lip, Gregory Y. H.
    Olsson, S. Bertil
    Prins, Martin H.
    Nieman, Fred H.
    Lopez-Sendon, Jose
    Vardas, Panos E.
    Aliot, Etienne
    Santini, Massimo
    Crijns, Harry J. G. M.
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 (24) : 3018 - 3026
  • [7] The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    Stangier, Joachim
    Rathgen, Karin
    Staehle, Hildegard
    Gansser, Dietmar
    Roth, Willy
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (03) : 292 - 303
1